CN104248756A - Anti-canine pseudorabies pharmaceutical composition - Google Patents
Anti-canine pseudorabies pharmaceutical composition Download PDFInfo
- Publication number
- CN104248756A CN104248756A CN201310263505.2A CN201310263505A CN104248756A CN 104248756 A CN104248756 A CN 104248756A CN 201310263505 A CN201310263505 A CN 201310263505A CN 104248756 A CN104248756 A CN 104248756A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- pseudorabies
- dog
- pharmaceutical composition
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to an anti-canine pseudorabies pharmaceutical composition. The pharmaceutical composition contains a swine pseudorabies vaccine and a diluting stroke-physiological saline solution or sterile water used for diluting the swine pseudorabies vaccine to the concentration equivalent to 0.5-0.05 time of the swine standard concentration with 1 swine/ml. The anti-canine pseudorabies pharmaceutical composition is used as a vaccine inoculating dogs, not only has no generation of a dog death case, but also can achieve an effect of effective prevention of the disease, and can significantly reduce the morbidity and the death rate because the dogs eat sick pork.
Description
Technical field
The present invention relates to veterinary biologics technical field, particularly one anti-dog pseudorabies pharmaceutical composition.
Background technology
Pseudorabies (Pseudorabies, PR) have another name called aujesky's disease (Aujeszky ' s Disease, AD), herpesvirus suis I type, very to itch disease etc., by pseudorabies virus (the Pseudorabies virus in herpetoviridae, Alphaherpesviridae, PRV or Aujeszky ' s Disease virus, ADV) one or more animal infected acute infectious disease of causing.Pseudorabies virus can cause the morbidity of multiple domestic animal and wild animal except the mankind and ape.In nature, virus may be present in wild rodents body, pig is the reservoir host of PRV, sick pig, be the major source of infection of dog pseudorabies with malicious Mus and sick dog, nose liquid, saliva, milk, urine and vaginal secretions that virus is passed through are discharged, can through digestive tract infection, also can through respiratory tract, surface wound and reproductive tract infection.
As can be seen from the above, PRV belongs to herpetoviridae, A type herpesviral subfamilies in classification.Nucleic acid based is distrand DNA.Although PRV only has 1 serotype, from the different strain virulence difference be to some extent separated all over the world, and, even pathogenic different to different animals of same strain.
Dog is animal the most responsive to this virus except rabbit, the morbidity that current dog infection Pseudorabies virus causes and death occur repeatedly, the people such as such as Liu Lei " are paying close attention to pseudorabies sufferer dog; it is just in face of you; the 6th scientific seminar of toy medical science branch of Chinese animal and veterinary association and veterinary surgery branch the 18 scientific seminar's collection of thesis Part I; toy medical science collected works, 56-59,2011." report dog because edible suffer from the Carnis Sus domestica of pseudorabies and pseudorabies occurs, and only in cerebral tissue, amplified genes of interest fragment from the PCR method tissue.
Prior art does not disclose anti-dog pseudorabies vaccines or relevant medicine, therefore, current Problems existing be need to research and develop a kind of can the vaccine of preventing canine pseudorabies, for reducing M & M caused after dog pseudorabies.
Summary of the invention
Technical problem to be solved by this invention is for the deficiencies in the prior art, provides a kind of anti-dog pseudorabies pharmaceutical composition.This pharmaceutical composition is mainly containing pseudorabies disease vaccine, said composition is used for immune dog class as vaccine, both there will not be dog class dead, the effect of effectively this disease of prevention can have been reached again, and can significantly reduce dog eat disease Carnis Sus domestica after caused M & M.
For this reason, the invention provides a kind of anti-dog pseudorabies pharmaceutical composition, wherein, pseudorabies disease vaccine and dilution physiological saline solution or sterilized water for described pseudorabies disease vaccine being diluted to the 0.5-0.05 times of concentration being equivalent to pig standard 1 part/ml is comprised in described compositions.
In a specific embodiment of the present invention, pseudorabies disease vaccine is utilized to prepare anti-dog pseudorabies pharmaceutical composition, and this anti-dog pseudorabies pharmaceutical composition is used for the prevention of dog pseudorabies as vaccine, concrete grammar is as follows: pseudorabies disease vaccine physiological saline solution is first diluted to pig standard 1 part/ml, carry out 2-20 with normal saline more doubly to dilute, anti-dog pseudorabies pharmaceutical composition is made after mixing, to healthy dogs by subcutaneous injection (or intramuscular injection, or collunarium) inoculate, 1ml/ is only.Described 2-20 doubly dilutes, and for the dog below 1 one full year of life, extension rate is preferably 10-20 and doubly dilutes, and for dog more than 1 one full year of life, extension rate is preferably 2-10 and doubly dilutes.
In the present invention, described pseudorabies disease vaccine is the vaccine for preventing porcine pseudorabies.
According to the present invention, described pseudorabies disease vaccine comprises swine pseudorabies vaccine, live vaccine, subunit vaccine and synthetic vaccine.Preferred described pseudorabies disease vaccine is pseudorabies disease live-vaccine.Preferred further, described pseudorabies disease vaccine is the natural gene-deleted strain of nature disappearance virulent gene or the genovariation strain of artificial disappearance virulent gene.
In an embodiment of the invention, described pseudorabies disease vaccine to be selected from pseudorabies disease live-vaccine (Bartha K-61 strain), pseudorabies disease live-vaccine (Bucharest strain), pseudorabies disease live-vaccine (HB-98 strain), pseudorabies disease live-vaccine (SA215 strain) one or more.
The present invention's " live vaccine " used one word, refers to from attenuation but still the vaccine prepared of the virus of the cell of reproducible host organisms.
The present invention's use " attenuation " one word, manually reduces pathogen toxicity for instigating virus forfeiture pathogenic but keeping antigenic mode to carry out sudden change to the gene relating to pathogen analytic metabolism.Usually, attenuation is realized by UV radiation, chemical treatment or external continuous high-order successive transfer culture.The change of outer aobvious gene, as made the specific nucleotide in known array lack or insert in viral genome by nucleotide, also may cause attenuation.
Term of the present invention " inactivated vaccine ", also referred to as inactivated vaccines, refers to as antigen to produce the suspension of the inactivation of viruses of immunity.The example of inactivated vaccine comprises whole virus vaccine and cracking type vaccine.Use known method can produce inactivated vaccine easily.Such as, by can whole virus vaccine be obtained by formalin process virus.Cracking type vaccine can be prepared by peplos after with ether process.
Term of the present invention " subunit vaccine " refers to the vaccine of the antigenic determinant comprised by extracting the purification separated from viral organism.It causes the probability of side reaction little than whole virus vaccine.Such as, from PRV (Pseudorabies virus) extract gD or gC albumen conventionally can be used for prepare subunit vaccine.
Term of the present invention " synthetic vaccine " refers to the vaccine formed primarily of chemosynthesis antigen or gene engineering antigen, antigenic determinant or peptide.
Term of the present invention " dog pseudorabies " refer to dog occur because infecting Pseudorabies virus following characteristics one or more: 1. sick dog shows as and is on the rack, and deliberately barks furiously, and does not react the call of owner, and two often in terrified shape; 2. very itch unbearably in a certain position of sick dog, first licks with tongue and lick, bite subsequently with tooth, and with the object friction of surrounding, with pawl scratching, position of very itching very soon speck, surrounding tissue swelling; 3. the case had loses above-mentioned symptom, but the groan of sick dog, there is pain in performance health somewhere; 4. sick dog to people and animals without aggressivity; 5. sick dog later stage excessive saliva, can not swallow, loss of appetite or absolutely useless; 6. the course of disease is rapid, and sick dog 36 hours endogenous causes of ill of being everlasting die of exhaustion.7. the viral nucleic acid in the tissues such as die of illness dog brain, liver, lung and spleen can be detected by PCR.
The present invention's predicate used " prevention " refers to by giving suppress Pseudorabies virus to infect according to vaccine combination of the present invention or postpone all behaviors of pseudorabies outbreak.Term " treatment " refers to all behaviors making Pseudorabies virus infect the symptom caused to alleviate or take a turn for the better by giving vaccine combination according to the present invention.
Term of the present invention " dog " refers to one of domestic animal that the mankind raise and train the earliest, also claims Canis familiaris L..The earliest by domestications (a lot of source) such as wolf (Canis lupus), jaokal, jackals (Cuon alpinus), now existing more than 200 kinds, as shepherd dog, Shiba Inu, sled dog, sleuth, Poodle etc.
As mentioned above, prior art does not disclose anti-dog pseudorabies vaccines or relevant medicine, and because pseudorabies genome is very large, for different genera, its toxic protein is inconsistent, and, the animal of different genera is also different to the sensitivity of vaccine, therefore, if to dog class Pigs Inoculated pseudorabies vaccines, not only can not effective preventing canine pseudorabies, after also easily causing dog vaccination, dog morbidity in 2-3 days is dead.
Applicant of the present invention, by lot of experiments, overcomes problems of the prior art, has researched and developed a kind of anti-dog pseudorabies pharmaceutical composition utilizing pseudorabies disease vaccine to prepare.Using the anti-dog pseudorabies pharmaceutical composition in the present invention as vaccination in dog class, both do not occur that dog class was dead, the effect of effectively this disease of prevention can have been reached again.The anti-dog pseudorabies pharmaceutical composition made according to the present invention's pseudorabies live vaccine as after vaccine immunity dog, can significantly reduce dog eat disease Carnis Sus domestica after caused M & M.
Accompanying drawing explanation
Below in conjunction with accompanying drawing, the present invention is described in further detail:
Fig. 1 is sick dead pig internal organs PCR qualification result;
In Fig. 1, the implication of Reference numeral is as follows:
M DL2000DNA Marker; 1 negative control; 2 positive controls;
3 No. 1 sick Pig Livers; 4 No. 2 sick Pig Livers; 5 No. 3 sick Pig Livers;
6 No. 1 sick Pulmonis Sus domestica samples; 7 No. 2 sick Pulmonis Sus domestica samples; 8 No. 3 sick Pulmonis Sus domestica samples.
Detailed description of the invention
For making the present invention easier to understand, describe the present invention in detail below in conjunction with drawings and Examples, these embodiments only play illustrative effect, are not limited to range of application of the present invention, NM specific experiment method in the following example, conveniently experimental technique carries out usually.
Embodiment
Embodiment 1:
Vaccine used in the present invention has: pseudorabies living vaccines (lot number: 1303003A, Pulaike Biological Engineering Co., Ltd. produce), pseudorabies disease live-vaccine (HB-98 strain) (lot number: 1303004, Chengdu medical instruments factory of Zhongmu Industry Co., Ltd produces), pseudorabies disease live-vaccine (lot number: 42LH, the biological large pharmaceutical factory of Spain Hai Bolai produces).
Main agents used in the present invention is porcine pseudorabies virus detectable is PRV (Pseudorabies virus) PCR detection kit (lot number: PR20120420, Anheal Laboratories Co., Ltd).
The present embodiment completes in Luoyang City periphery three dog fields, is numbered dog field A, dog field B and dog field C respectively.Dog field A and C is tibetan mastiff field, and dog field B is small-sized dog dog field, manages and has different kind of dog.
1, animal grouping:
Dog field A and the dog below C random selecting 1 one full year of life 20, more than 1 one full year of life each 20 of dog, be divided into 2 groups, 10/group respectively at random, and one group is the immune group of Pigs Inoculated pseudorabies living vaccines, and another group is not vaccinated matched group; Dog below B random selecting 1 one full year of life of dog field 10, dog more than 1 one full year of life 10, is divided into 2 groups respectively at random, 5/group, and one group is the immune group of Pigs Inoculated pseudorabies living vaccines, and another group is not vaccinated matched group.3 dog fields use the pseudorabies disease live-vaccine of 3 different cultivars respectively.2, vaccination:
1) immunity inoculation of dog below 1 one full year of life: get vaccine, after vaccine being diluted to 1 part/ml with physiological saline solution, 15 times of dilutions are carried out again with physiological saline solution, make anti-dog pseudorabies pharmaceutical composition, and subcutaneous vaccination is carried out to immune group dog, only, matched group dog subcutaneous vaccination physiological saline solution 1ml/ only for 1ml/.
2) 1 one full year of life above dog immunity inoculation: get vaccine, after vaccine being diluted to 1 part/ml with physiological saline solution, 5 times of dilutions are carried out again with physiological saline solution, make anti-dog pseudorabies pharmaceutical composition, and subcutaneous vaccination is carried out to immune group dog, only, matched group dog subcutaneous vaccination physiological saline solution 1ml/ only for 1ml/.
3) after vaccination every day viewing test dog clinical symptoms.
3, the detection of immune effect:
Latter 3 weeks of immunity, dog isolated rearing will be tested, get porcine pseudorabies to die of illness piglets (about 50 age in days) liver or lungs (totally 3 sick dead pig, be numbered 1 respectively, 2 and No. 3 sick pigs, from same morbidity pig farm, nervous symptoms in various degree is all shown as before dead, lethargy, vomiting and heating, after death get liver and the detection of lungs use PRV (Pseudorabies virus) PCR detection kit, result is the positive, see Fig. 1), feeding immune group and matched group dog while of being chopped into after fritter together with Carnis Sus domestica, feeding 2 times in 1 day, 1 one full year of life above dog be about 100g/ only/time, dog below 1 one full year of life is about 50g//time, then normally raise, observe clinical symptoms and the death condition of dog every day, Continuous Observation 7 days.
4, result:
1) will make after anti-dog pseudorabies pharmaceutical composition inoculates dog class as vaccine, in three dog fields 25 vaccinated dogs only 2 there is body temperature rising, the dog that appetite reduces, and these 2 dogs are the dog of below 1 one full year of life, namely recover normal after 2 days.The clinical manifestation only of all the other dogs is all normal, shows that this vaccine is safe to dog.
2) immune effect: after immunity 3 weeks, feeding 2 pseudorabies are died of illness after haslet and Carnis Sus domestica, only 100% morbidity dead of the matched group dog of three dog fields, all morbidities in 3-4 days after the sick haslet of feeding and Carnis Sus domestica, death in latter 36 hours of falling ill; Only only 1 death of immune group dog, fall ill all similar to matched group with death time, clinical symptoms, all the other homodesmic work, refer to table 1, show that pseudorabies live vaccine can in the effective immunoreation of dog Immune inducing in vivo.The results detailed in Table 2.
Table 1: test dog clinical manifestation log after feeding sick dead pig internal organs and Carnis Sus domestica
Table 2: pseudorabies live vaccine is to the immune effect of dog
As can be seen from above-described embodiment, using the anti-dog pseudorabies pharmaceutical composition made with pseudorabies disease vaccine as vaccination in dog class, both do not occurred that dog class was dead, the effect of effectively this disease of prevention can be reached again, and can significantly reduce dog eat disease Carnis Sus domestica after caused M & M.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (5)
1. an anti-dog pseudorabies pharmaceutical composition, it is characterized in that, in described compositions, comprising pseudorabies disease vaccine and dilution physiological saline solution or sterilized water for described pseudorabies disease vaccine being diluted to the 0.5-0.05 times of concentration being equivalent to pig standard 1 part/ml.
2. pharmaceutical composition according to claim 1, is characterized in that, described pseudorabies disease vaccine comprises swine pseudorabies vaccine, live vaccine, subunit vaccine and synthetic vaccine.
3. pharmaceutical composition according to claim 2, is characterized in that, described pseudorabies disease vaccine is pseudorabies disease live-vaccine.
4. pharmaceutical composition according to claim 3, is characterized in that, described pseudorabies disease vaccine is the natural gene-deleted strain of nature disappearance virulent gene or the genovariation strain of artificial disappearance virulent gene.
5. pharmaceutical composition according to claim 4, it is characterized in that, described pseudorabies disease vaccine to be selected from pseudorabies disease live-vaccine (Bartha K-61 strain), pseudorabies disease live-vaccine (Bucharest strain), pseudorabies disease live-vaccine (HB-98 strain), pseudorabies disease live-vaccine (SA215 strain) one or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310263505.2A CN104248756A (en) | 2013-06-27 | 2013-06-27 | Anti-canine pseudorabies pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310263505.2A CN104248756A (en) | 2013-06-27 | 2013-06-27 | Anti-canine pseudorabies pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104248756A true CN104248756A (en) | 2014-12-31 |
Family
ID=52184230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310263505.2A Pending CN104248756A (en) | 2013-06-27 | 2013-06-27 | Anti-canine pseudorabies pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104248756A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101081298A (en) * | 2007-06-26 | 2007-12-05 | 陈少莺 | Method for preparation of novel subunit vaccine for treating porcine pseudorabies |
| CN102690791A (en) * | 2011-10-25 | 2012-09-26 | 哈药集团生物疫苗有限公司 | Method for generating porcine pseudorabies virus by culturing ST cell in microcarrier of bioreactor |
-
2013
- 2013-06-27 CN CN201310263505.2A patent/CN104248756A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101081298A (en) * | 2007-06-26 | 2007-12-05 | 陈少莺 | Method for preparation of novel subunit vaccine for treating porcine pseudorabies |
| CN102690791A (en) * | 2011-10-25 | 2012-09-26 | 哈药集团生物疫苗有限公司 | Method for generating porcine pseudorabies virus by culturing ST cell in microcarrier of bioreactor |
Non-Patent Citations (2)
| Title |
|---|
| 刘涛等: "猪伪狂犬疫苗研究进展", 《兽医导刊》 * |
| 袁子国等: "猪伪狂犬病病毒疫苗株Bartha-K61在犬科动物体内的安全性评价及免疫实验", 《中国兽医学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Prevention and control strategies of African swine fever and progress on pig farm repopulation in China | |
| CN100354414C (en) | Pseudo-rabies gE/gI-gene loss poison strain, killed vaccine containing it and use | |
| Fulton et al. | Bovine coronavirus (BCV) infections in transported commingled beef cattle and sole-source ranch calves | |
| CN103347534B (en) | Bovine viral diarrhea virus 1b types vaccine composition and method | |
| Scagliarini et al. | Orf in South Africa: endemic but neglected | |
| Kaden et al. | An update on safety studies on the attenuated “RIEMSER® Schweinepestoralvakzine” for vaccination of wild boar against classical swine fever | |
| Liang et al. | Understanding the research advances on lumpy skin disease: A comprehensive literature review of experimental evidence | |
| Kaiser et al. | Influenza A virus shedding reduction observed at 12 weeks post‐vaccination when newborn pigs are administered live‐attenuated influenza virus vaccine | |
| CN105671003A (en) | Infectious bronchitis low-virulent live vaccine YX10 D90 strain | |
| CN108392628A (en) | A kind of porcine mycoplasmal pneumonia inactivated vaccine and preparation method thereof | |
| Gao et al. | The new porcine epidemic diarrhea virus outbreak may mean that existing commercial vaccines are not enough to fully protect against the epidemic strains | |
| Kumar et al. | Emergence and transboundary spread of lumpy skin disease in South Asia | |
| Muuka et al. | Evaluation of new generation macrolides for the treatment and metaphylaxis of contagious bovine pleuropneumonia (CBPP) in cattle experimentally infected with Mycoplasma mycoides subspecies mycoides | |
| Chung et al. | Effectiveness of a BHV-1/BEFV bivalent vaccine against bovine herpesvirus type 1 infection in cattle | |
| CN106190988B (en) | Inactivated vaccine of feline calicivirus CH-JL5 strain | |
| Zewdie et al. | A review of foot-and-mouth disease in Ethiopia: epidemiological aspects, economic implications, and control strategies | |
| Chao et al. | Different rabies outbreaks on two beef cattle farms in the same province of China: Diagnosis, virus characterization and epidemiological analysis | |
| Nelson | Infectious bovine rhinotracheitis (Herpesvirus bovis) infection in swine | |
| Boonsoongnern et al. | The prevalence of Mycoplasma hyopneumoniae in commercial suckling pigs in Thailand | |
| Amin et al. | Emergence and transboundry spread of lumpy skin disease in South Asian Countries: a review | |
| CN104248756A (en) | Anti-canine pseudorabies pharmaceutical composition | |
| Oliver et al. | Experimental intramammary infection with a strain of Escherichia coli isolated from a cow with persistent E. coli mastitis | |
| CN111097044A (en) | Canine leptospira, icterohepaemic leptospira and canine coronavirus triple inactivated vaccine | |
| Kasimanickam et al. | A field study of the effects of a monovalent Leptospira borgpetersenii serovar Hardjo strain hardjobovis vaccine administered with oxytetracycline on reproductive performance in beef cattle | |
| Parajuli et al. | Foot and mouth disease (FMD) among animals in Nepal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141231 |
|
| RJ01 | Rejection of invention patent application after publication |